Drugs / IPV vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01277705 | Jan → Apr 2002 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03460405 Comparator | Jul 2018 → Dec 2019 | — | PT Bio Farma | Completed | No outcome recorded |
| Phase 3 | NCT02458183 Comparator | Feb 2015 → Dec 2017 | diphtheria, pertussis, poliomyelitis, tetanus | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPV Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03460405 ↗ |
| Known as | inactivated poliovirus vaccine | “compared to Boostrix™ and inactivated poliovirus vaccine administered separately, and with Revaxis®” NCT01277705 ↗ |
| Modality | Vaccine | “compared to Boostrix™ and inactivated poliovirus vaccine administered separately, and with Revaxis®” NCT01277705 ↗ |
| Route | Intramuscular | “A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of left thigh” NCT02458183 ↗ |